Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia
August 08 2017 - 7:00AM
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new
generation of drugs within human and veterinary oncology, announced
today that it has received marketing approval of Doxophos in
Russia, a key milestone following the recently established
relationship with Hetero Group, its new marketing and distribution
partner.
Doxophos has been approved for use in the treatment of acute
lymphoblastic leukemia, acute myeloblastic leukemia, chronic
leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, multiple
myeloma, osteogenic sarcoma, Ewing’s sarcoma, soft tissue sarcoma,
neuroblastoma, rhabdomyosarcoma, Wilms’ tumor, breast carcinoma,
endometrial cancer, ovarian carcinoma, germ cell tumors, prostatic
carcinoma, lung cancer, gastric carcinoma, head and neck cancer and
thyroid carcinoma.
Doxophos is a hybrid and novel nanoparticle formulation of
doxorubicin, one of the most commonly used anti-cancer substances
in the world, well-recognized for its treatment of lung, breast and
prostate cancer, among others. Doxorubicin is the active substance
in the prominent oncology family of brands including Adriamycin®
and Doxil®, totaling an estimated market value of $800 million
USD in 2015 and expected to reach $1.4 billion by 2024.
As is its current practice with Paclical, Oasmia’s leading and
previously commercialized cancer treatment product, Hetero Group
will be responsible for the marketing and distribution of Doxophos
in Russia.
“We are pleased that we were able to follow through on our
previously stated objective of commercializing Doxophos, a product
that we believe represents important high growth market
opportunity, in Russia” said Julian Aleksov, Executive Chairman of
Oasmia Pharmaceutical AB. ”We are also confident that this product
will add significant value to the marketing and distribution
efforts of Hetero, our new partner with whom we look forward to
work in these regions and presumably others in the future.”
Notes to
editors:
About Doxophos
Doxophos is a novel nanoparticle formulation of doxorubicin in
combination with Oasmia’s patented technology XR17. Doxorubicin is
one of the oldest and most widely used anti-cancer substances in
the world and is used to treat a variety of different forms of
cancer such as acute lymphoblastic leukemia, acute myeloblastic
leukemia, chronic leukemia, Hodgkin’s disease and non-Hodgkin’s
lymphoma, multiple myeloma, osteogenic sarcoma, Ewing’s sarcoma,
soft tissue sarcoma, neuroblastoma, rhabdomyosarcoma, Wilms’ tumor,
breast carcinoma, endometrial cancer, ovarian carcinoma, germ cell
tumors, prostatic carcinoma, lung cancer, gastric carcinoma, head
and neck cancer and thyroid carcinoma.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and
sells new generations of drugs in the field of human and veterinary
oncology. The company’s product development aims to create and
manufacture novel nanoparticle formulations and drug-delivery
systems based on well-established cytostatics which, in comparison
with current alternatives, show improved properties, reduced
side-effects, and expanded applications. The company’s product
development is based on its proprietary in-house research and
company patents. Oasmia is listed on NASDAQ Capital Markets
(OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365)
and NASDAQ Stockholm (OASM.ST).
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0ad451dd-390e-4306-84a0-a97d31a11992
For more information:
Julian Aleksov, Executive Chairman
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com
Media Contact :
Eric Fischgrund - FischTank Marketing and PR
Tel : 646 699 1414
E-mail : eric@fischtankpr.com
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From Sep 2023 to Sep 2024